This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Kosmalski M., Ziółkowska S., Czarny P., Szemraj J., Pietras T.: The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Med., 2022; 11: 1375KosmalskiM.ZiółkowskaS.CzarnyP.SzemrajJ.PietrasT.The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitusJ Clin Med2022111375Search in Google Scholar
Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol., 2013; 58: 593–608BlachierM.LeleuH.Peck-RadosavljevicM.VallaD.C.Roudot-ThoravalF.The burden of liver disease in Europe: a review of available epidemiological dataJ Hepatol201358593608Search in Google Scholar
Younossi Z. M., Golabi P., de Avila L., Paik J. M., Srishord M., Fukui N., Qiu Y., Burns L., Afendy A., & Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol., 2019; 71: 793–801YounossiZ. M.GolabiP.de AvilaL.PaikJ. M.SrishordM.FukuiN.QiuY.BurnsL.AfendyA.NaderF.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysisJ Hepatol201971793801Search in Google Scholar
Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006; 368: 1696–705DruckerD.J.NauckM.A.The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet20063681696705Search in Google Scholar
Filippatos T.D., Panagiotopoulou T.V., Elisaf M.S.. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud RDS., 2014; 11: 202FilippatosT.D.PanagiotopoulouT.V.ElisafM.S.Adverse effects of GLP-1 receptor agonistsRev Diabet Stud RDS201411202Search in Google Scholar
He Z., Gao Y., Lieu L., Afrin S., Cao J., Michael N.J., Dong Y., Sun J., Guo H., Williams K.W. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons—Implications for energy balance and glucose control. Mol Metab., 2019; 28: 120–134HeZ.GaoY.LieuL.AfrinS.CaoJ.MichaelN.J.DongY.SunJ.GuoH.WilliamsK.W.Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons—Implications for energy balance and glucose controlMol Metab201928120134Search in Google Scholar
Wadden T.A., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., Aronne L.; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes., 2013; 37: 1443–51WaddenT.A.HollanderP.KleinS.NiswenderK.WooV.HaleP.M.AronneL.NN8022-1923 InvestigatorsWeight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized studyInt J Obes201337144351Search in Google Scholar
Monami M., Dicembrini I., Marchionni N., Rotella C.M., Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res., 2012: 672658MonamiM.DicembriniI.MarchionniN.RotellaC.M.MannucciE.Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysisExp Diabetes Res2012672658Search in Google Scholar
Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al. STEP 1 Study Group: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med., 2021; 384: 989–1002WildingJ.P.H.BatterhamR.L.CalannaS.DaviesM.Van GaalL.F.LingvayI.McGowanB.M.RosenstockJ.TranM.T.D.WaddenT.A.STEP 1 Study Group: Once-weekly semaglutide in adults with overweight or obesityN Engl J Med20213849891002Search in Google Scholar
Davies M., Færch L., Jeppesen O.K., Pakseresht A., Pedersen S.D., Perreault L., Rosenstock J., Shimomura I., Viljoen A., Wadden T.A., et al., STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet., 2021; 397: 971–984DaviesM.FærchL.JeppesenO.K.PaksereshtA.PedersenS.D.PerreaultL.RosenstockJ.ShimomuraI.ViljoenA.WaddenT.A.STEP 2 Study GroupSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialThe Lancet2021397971984Search in Google Scholar
Rubino D., Abrahamsson N., Davies M., Hesse D., Greenway F.L., Jensen C., Lingvay I., Mosenzon O., Rosenstock J., Rubio M.A., et al., STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults With over-weight or obesity: The STEP 4 randomized clinical trial. JAMA., 2021; 325: 1414–1425RubinoD.AbrahamssonN.DaviesM.HesseD.GreenwayF.L.JensenC.LingvayI.MosenzonO.RosenstockJ.RubioM.A.STEP 4 InvestigatorsEffect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults With over-weight or obesity: The STEP 4 randomized clinical trialJAMA202132514141425Search in Google Scholar
Kadowaki T., Isendahl J., Khalid U., Lee S.Y., Nishida T., Ogawa W., Tobe K., Yamauchi T., Lim S., STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol., 2022 10: 193–206KadowakiT.IsendahlJ.KhalidU.LeeS.Y.NishidaT.OgawaW.TobeK.YamauchiT.LimS.STEP 6 investigatorsSemaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trialLancet Diabetes Endocrinol202210193206Search in Google Scholar
Rubino D.M., Greenway F.L., Khalid U., O’Neil P.M., Rosenstock J., Sørrig R., Wadden T.A., Wizert A., Garvey W.T., STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults With overweight or obesity without diabetes: The STEP 8 Randomized Clinical Trial. JAMA., 2022; 327: 138–150RubinoD.M.GreenwayF.L.KhalidU.O’NeilP.M.RosenstockJ.SørrigR.WaddenT.A.WizertA.GarveyW.T.STEP 8 InvestigatorsEffect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults With overweight or obesity without diabetes: The STEP 8 Randomized Clinical TrialJAMA2022327138150Search in Google Scholar
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity, Available at: https://www.prnewswire.com/news-releases/wegovy-demonstrated-significant-and-sustained-weight-loss-in-two-year-study-in-adults-with-obesity-301417583.html (Accessed September 26, 2022)Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesityAvailable at: https://www.prnewswire.com/news-releases/wegovy-demonstrated-significant-and-sustained-weight-loss-in-two-year-study-in-adults-with-obesity-301417583.html (Accessed September 26, 2022)Search in Google Scholar
Wadden T.A., Bailey T.S., Billings L.K., Davies M., Frias J.P., Koroleva A., Lingvay I., O’Neil P.M., Rubino D.M., Skovgaard D., et al., STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with over-weight or obesity: The STEP 3 Randomized Clinical Trial. JAMA., 2021; 325: 1403–1413WaddenT.A.BaileyT.S.BillingsL.K.DaviesM.FriasJ.P.KorolevaA.LingvayI.O’NeilP.M.RubinoD.M.SkovgaardD.STEP 3 InvestigatorsEffect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with over-weight or obesity: The STEP 3 Randomized Clinical TrialJAMA202132514031413Search in Google Scholar
Jabbour S.A., Frías J.P., Guja C., Hardy E., Ahmed A., Öhman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. czerwiec 2018; 20: 1515–9JabbourS.A.FríasJ.P.GujaC.HardyE.AhmedA.ÖhmanP.Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 studyDiabetes Obes Metabczerwiec20182015159Search in Google Scholar
Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: Review of management for primary care providers. Mayo Clin Proc., wrzesień 2022; 97: 1700–16BasuRNoureddinMClarkJM.Nonalcoholic fatty liver disease: Review of management for primary care providersMayo Clin Procwrzesień202297170016Search in Google Scholar
Kosmalski M., Drzewoski J., Szymczak-Pajor I., Zieleniak A., Mikołajczyk-Solińska M., Kasznicki J., Śliwińska A.. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines, 2022; 10: 2253KosmalskiM.DrzewoskiJ.Szymczak-PajorI.ZieleniakA.Mikołajczyk-SolińskaM.KasznickiJ.ŚliwińskaA.Irisin is related to non-alcoholic fatty liver disease (NAFLD)Biomedicines2022102253Search in Google Scholar
Cichoż-Lach H. Obesity and non-alcoholic fatty liver disease. In: Clinical Obesitology. Bielsko-Biała: Alfa-Medica Press; 2021: 206–15Cichoż-LachH.Obesity and non-alcoholic fatty liver diseaseIn:Clinical ObesitologyBielsko-BiałaAlfa-Medica Press202120615Search in Google Scholar
Ghosal S., Datta D., Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 11 listopad 2021; 11: 22063GhosalS.DattaD.SinhaB.A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)Sci Rep11listopad20211122063Search in Google Scholar
Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin., 2008; 24: 275–286KlonoffD.C.BuseJ.B.NielsenL.L.GuanX.BowlusC.L.HolcombeJ.H.WintleM.E.MaggsD.G.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin200824275286Search in Google Scholar
Armstrong M.J., Houlihan D.D., Rowe I.A., Clausen W.H., Elbrønd B., Gough S.C., Tomlinson J.W., Newsome P.N. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther., 2013; 37: 234–242ArmstrongM.J.HoulihanD.D.RoweI.A.ClausenW.H.ElbrøndB.GoughS.C.TomlinsonJ.W.NewsomeP.N.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD programAliment Pharmacol Ther201337234242Search in Google Scholar
Jendle J., Nauck M.A., Matthews D.R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B.J., Garber A.J.; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab., 2009; 11: 1163–72JendleJ.NauckM.A.MatthewsD.R.FridA.HermansenK.DüringM.ZdravkovicM.StraussB.J.GarberA.J.LEAD-2 and LEAD-3 Study GroupsWeight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissueDiabetes Obes Metab200911116372Search in Google Scholar
Petit J.M., Cercueil J.P., Loffroy R., Denimal D., Bouillet B., Fourmont C., Chevallier O., Duvillard L., Vergès B. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab., 2017;102: 407–415PetitJ.M.CercueilJ.P.LoffroyR.DenimalD.BouilletB.FourmontC.ChevallierO.DuvillardL.VergèsB.Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD StudyJ Clin Endocrinol Metab2017102407415Search in Google Scholar
Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K.; LEAN trial team, Abouda G., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387: 679–690ArmstrongM.J.GauntP.AithalG.P.BartonD.HullD.ParkerR.HazlehurstJ.M.GuoK.LEAN trial teamAboudaG.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 studyLancet2016387679690Search in Google Scholar
Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., Sanyal AJ, Sejling AS, Harrison SA; et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med., 2021; 384: 1113–1124NewsomeP.N.BuchholtzK.CusiK.LinderM.OkanoueT.RatziuV.SanyalAJSejlingASHarrisonSAA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisN Engl J Med202138411131124Search in Google Scholar
Péterfi Z., Szilvásy-Szabó A., Farkas E., Ruska Y., Pyke C., Knudsen L.B., Fekete C. Glucagon-like peptide-1 regulates the proopiomelanocortin neurons of the arcuate nucleus both directly and indirectly via presynaptic action. Neuroendocrinology, 2021; 111: 986–997PéterfiZ.Szilvásy-SzabóA.FarkasE.RuskaY.PykeC.KnudsenL.B.FeketeC.Glucagon-like peptide-1 regulates the proopiomelanocortin neurons of the arcuate nucleus both directly and indirectly via presynaptic actionNeuroendocrinology2021111986997Search in Google Scholar
Müller T.D., Finan B., Bloom S.R., D’Alessio D., Drucker D.J., Flatt P.R., Fritsche A., Gribble F., Grill H.J., Habener J.F., et al. Glucagon-like peptide 1 (GLP-1). Mol Metab., 2019; 30: 72–130MüllerT.D.FinanB.BloomS.R.D’AlessioD.DruckerD.J.FlattP.R.FritscheA.GribbleF.GrillH.J.HabenerJ.F.Glucagon-like peptide 1 (GLP-1)Mol Metab20193072130Search in Google Scholar
Heppner K.M., Kirigiti M., Secher A., Paulsen S.J., Buckingham R., Pyke C., Knudsen L.B., Vrang N., Grove K.L. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology, 2015; 156: 255–267HeppnerK.M.KirigitiM.SecherA.PaulsenS.J.BuckinghamR.PykeC.KnudsenL.B.VrangN.GroveK.L.Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brainEndocrinology2015156255267Search in Google Scholar
Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP–1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res., 2011; 89: 481–489HamiltonA.PattersonS.PorterD.GaultV.A.HolscherC.Novel GLP–1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brainJ Neurosci Res201189481489Search in Google Scholar
Athauda D., Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today, 2016; 21: 802–818AthaudaD.FoltynieT.The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionDrug Discov Today201621802818Search in Google Scholar
Spielman L.J., Gibson D.L., Klegeris A. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. Eur J Cell Biol., 2017; 96: 240–253SpielmanL.J.GibsonD.L.KlegerisA.Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factorsEur J Cell Biol201796240253Search in Google Scholar
Timper K., Del Río–Martín A., Cremer A.L., Bremser S., Alber J., Giavalisco P., Varela L., Heilinger C., Nolte H., Trifunovic A., et al. GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function. Cell Metab., 2020; 31: 1189–1205.e13TimperK.Del Río–MartínA.CremerA.L.BremserS.AlberJ.GiavaliscoP.VarelaL.HeilingerC.NolteH.TrifunovicA.GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and functionCell Metab20203111891205.e13Search in Google Scholar
Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, et al. Central and peripheral GLP–1 systems independently suppress eating. Nat Metab. 2021; 3(2): 258–273.BrierleyDIHoltMKSinghAde AraujoAMcDougleMVergaraMAfaghaniMHLeeSJScottKMaskeCCentral and peripheral GLP–1 systems independently suppress eatingNat Metab202132258273Search in Google Scholar
Głombik K., Detka J., Budziszewska B. Hormonal regulation of oxidative phosphorylation in the brain in health and disease. Cells, 2021;10: 2937GłombikK.DetkaJ.BudziszewskaB.Hormonal regulation of oxidative phosphorylation in the brain in health and diseaseCells2021102937Search in Google Scholar
Farr O.M., Upadhyay J., Rutagengwa C., DiPrisco B., Ranta Z., Adra A., Bapatla N., Douglas V.P., Douglas K.A.A., Nolen-Doerr E., et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab., 2019; 21: 2459–2464FarrO.M.UpadhyayJ.RutagengwaC.DiPriscoB.RantaZ.AdraA.BapatlaN.DouglasV.P.DouglasK.A.A.Nolen-DoerrE.Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapiesDiabetes Obes Metab20192124592464Search in Google Scholar
Seghieri M., Rebelos E., Gastaldelli A., Astiarraga B.D., Casolaro A., Barsotti E., Pocai A., Nauck M., Muscelli E., Ferrannini E. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia., 2013; 56: 156–161SeghieriM.RebelosE.GastaldelliA.AstiarragaB.D.CasolaroA.BarsottiE.PocaiA.NauckM.MuscelliE.FerranniniE.Direct effect of GLP-1 infusion on endogenous glucose production in humansDiabetologia201356156161Search in Google Scholar
Gastaldelli A., Gaggini M., Daniele G., Ciociaro D., Cersosimo E., Tripathy D., Triplitt C., Fox P., Musi N., DeFronzo R., et al. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016; 64: 2028–2037GastaldelliA.GagginiM.DanieleG.CiociaroD.CersosimoE.TripathyD.TriplittC.FoxP.MusiN.DeFronzoR.Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography studyHepatology20166420282037Search in Google Scholar
Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., Anania F.A. Glucagon–like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010; 51: 1584–1592GuptaN.A.MellsJ.DunhamR.M.GrakouiA.HandyJ.SaxenaN.K.AnaniaF.A.Glucagon–like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayHepatology20105115841592Search in Google Scholar
Pyke C., Heller R.S., Kirk R.K., Ørskov C., Reedtz-Runge S., Kaastrup P., Hvelplund A., Bardram L., Calatayud D., Knudsen L.B. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 2014; 155: 1280–1290PykeC.HellerR.S.KirkR.K.ØrskovC.Reedtz-RungeS.KaastrupP.HvelplundA.BardramL.CalatayudD.KnudsenL.B.GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibodyEndocrinology201415512801290Search in Google Scholar
Seghieri M., Christensen A.S., Andersen A., Solini A., Knop F.K., Vilsbøll T. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne), 2018; 9: 649SeghieriM.ChristensenA.S.AndersenA.SoliniA.KnopF.K.VilsbøllT.Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLDFront Endocrinol (Lausanne)20189649Search in Google Scholar
Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., Faraci G., Pacetti D., Vivarelli M., Nicolini D., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int., 2011; 31: 1285–1297Svegliati-BaroniG.SaccomannoS.RychlickiC.AgostinelliL.De MinicisS.CandelaresiC.FaraciG.PacettiD.VivarelliM.NicoliniD.Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitisLiver Int20113112851297Search in Google Scholar
Oliveira F.C.B., Bauer E.J., Ribeiro C.M., Pereira S.A., Beserra B.T.S., Wajner S.M., Maia A.L., Neves F.A.R., Coelho M.S., Amato A.A. Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue. Front Endocrinol (Lausanne). 2022; 12: 803363OliveiraF.C.B.BauerE.J.RibeiroC.M.PereiraS.A.BeserraB.T.S.WajnerS.M.MaiaA.L.NevesF.A.R.CoelhoM.S.AmatoA.A.Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissueFront Endocrinol (Lausanne)202212803363Search in Google Scholar
Marín-Juez R., Jong-Raadsen S., Yang S., Spaink H.P. Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish. J Endocrinol., 2014; 222: 229–241Marín-JuezR.Jong-RaadsenS.YangS.SpainkH.P.Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafishJ Endocrinol2014222229241Search in Google Scholar
Lu Y., Jiang Z., Dai H., Miao R., Shu J., Gu H., Liu X., Huang Z., Yang G., Chen A.F., et al. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway. Hepatology. 2018; 67: 1303–1319LuY.JiangZ.DaiH.MiaoR.ShuJ.GuH.LiuX.HuangZ.YangG.ChenA.F.Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathwayHepatology20186713031319Search in Google Scholar
Xu E., Forest M.P., Schwab M., Avramoglu R.K., St-Amand E., Caron A.Z., Bellmann K., Shum M., Voisin G., Paquet M., et al. Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ. Hepatology, 2014; 59: 1803–1815XuE.ForestM.P.SchwabM.AvramogluR.K.St-AmandE.CaronA.Z.BellmannK.ShumM.VoisinG.PaquetM.Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγHepatology20145918031815Search in Google Scholar
Yu P., Xu X., Zhang J., Xia X., Xu F., Weng J., Lai X., Shen Y. Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway. Int J Endocrinol., 2019; 19: 1567095YuP.XuX.ZhangJ.XiaX.XuF.WengJ.LaiX.ShenY.Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathwayInt J Endocrinol2019191567095Search in Google Scholar
Kim E.R., Park J.S., Kim J.H., Oh J.Y., Oh I.J., Choi D.H., Lee Y.S., Park I.S., Kim S., Lee D.H., et al. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. Hepatology, 2022; 75: 1523–1538KimE.R.ParkJ.S.KimJ.H.OhJ.Y.OhI.J.ChoiD.H.LeeY.S.ParkI.S.KimS.LeeD.H.A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiomeHepatology20227515231538Search in Google Scholar